Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C118803-1mg | 1mg | In stock | $127.90 | |
C118803-5mg | 5mg | In stock | $572.90 | |
C118803-25mg | 25mg | In stock | $2,577.90 |
Potent, selective μ opioid antagonist
Synonyms | CTAP|103429-32-9|CHEMBL1795717|TCTAP|(4R,7S,10S,13R,16S,19R)-N-[(2S,3R)-1-Amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol- |
---|---|
Specifications & Purity | Moligand™, ≥95% |
Biochemical and Physiological Mechanisms | Selective μ-opioid receptor antagonist.Potent and selective μ opioid receptor antagonist (1200-fold more selective vs . δ receptor). Blood-brain barrier permeable and active in vivo . Antagonizes antinociceptive effect.CTAP is a polypeptide antagonist pre |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | ANTAGONIST |
Mechanism of action | Antagonist of δ receptor;Antagonist of μ receptor |
Note | This product is supplied in one (or more) pack size which is freeze dried. Therefore the contents may not be readily visible, as they can coat the bottom or walls of the vial. Please see our FAQs and information page for more details on handling. Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one week. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | Amino Acid Sequence Phe-Cys-Tyr-Trp-Arg-Thr-Pen-Thr-NH2 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (4R,7S,10S,13R,16S,19R)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-10-[3-(diaminomethylideneamino)propyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide |
---|---|
INCHI | InChI=1S/C51H69N13O11S2/c1-26(65)39(42(53)68)62-49(75)41-51(3,4)77-76-25-38(61-43(69)33(52)21-28-11-6-5-7-12-28)47(73)59-36(22-29-16-18-31(67)19-17-29)45(71)60-37(23-30-24-57-34-14-9-8-13-32(30)34)46(72)58-35(15-10-20-56-50(54)55)44(70)63-40(27(2)66)48(74)64-41/h5-9,11-14,16-19,24,26-27,33,35-41,57,65-67H,10,15,20-23,25,52H2,1-4H3,(H2,53,68)(H,58,72)(H,59,73)(H,60,71)(H,61,69)(H,62,75)(H,63,70)(H,64,74)(H4,54,55,56)/t26-,27-,33-,35+,36+,37-,38+,39+,40+,41-/m1/s1 |
InChi Key | OFMQLVRLOGHAJI-FGHAYEPSSA-N |
Canonical SMILES | CC(C1C(=O)NC(C(SSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)(C)C)C(=O)NC(C(C)O)C(=O)N)O |
Isomeric SMILES | C[C@H]([C@H]1C(=O)N[C@@H](C(SSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC=CC=C5)N)(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)O |
WGK Germany | 3 |
PubChem CID | 10418702 |
Molecular Weight | 1104.3 |
PubChem CID | 44309215 |
---|---|
BindingDB Ligand | 50020210 |
CAS Registry No. | 103429-32-9 |
GPCRdb Ligand | CTAP |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
E1527197 | Certificate of Analysis | Jan 06, 2023 | C118803 |
J2229167 | Certificate of Analysis | Sep 23, 2022 | C118803 |
J2229168 | Certificate of Analysis | Sep 23, 2022 | C118803 |
J2229169 | Certificate of Analysis | Sep 23, 2022 | C118803 |
B2225353 | Certificate of Analysis | Dec 23, 2021 | C118803 |
WGK Germany | 3 |
---|
1. Furukawa A et al.. (2018) Endothelin Signaling Contributes to Modulation of Nociception in Early-stage Tongue Cancer in Rats.. Anesthesiology, 128 (6): (1207-1219). [PMID:29461271] |